SER-AP-ES
LOE ApproachingNDAORALTABLET
Approved
Feb 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SER-AP-ES is an oral small-molecule tablet approved by Novartis in 1960 with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature portfolio requiring transition planning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for this product. Working on SER-AP-ES offers stability in a mature franchise but limited growth trajectory, making it suitable for consolidation or portfolio exit roles.
Brand ManagerCommercial Operations Analyst
Worked on SER-AP-ES at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.